Access cutting-edge head and neck squamous cell carcinoma treatment through this phase 2 clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Duarte location
Preparing your pre-screening questions…
Access head and neck squamous cell carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related head and neck squamous cell carcinoma treatment provided free
Check if you qualify for this head and neck squamous cell carcinoma clinical trial in Duarte, CA
No-Cost Study Care
Local to Duarte
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein will be enrolled. Approximately 180 participants will be enrolled in the study at sites worldwide. Participants will receive intravenous doses of telisotuzumab adizutecan with intravenous pembrolizumab, or standard of care (SOC) chemotherapy with pembrolizumab. Participants will receive treatment as part of a 67 weeks study duration. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits every 3 weeks during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Sponsor: AbbVie
Yes, this clinical trial (NCT07744126) has an active research site in Duarte, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for head and neck squamous cell carcinoma treatment options in Duarte, CA, this clinical trial (NCT07744126) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Duarte research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced head and neck squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all head and neck squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Duarte — not just this study.
Browse Alzheimers Disease Trials in Duarte →